Cellular Immunotherapy Study for Brain Cancer

Completed · Phase 1

Conditions studied: Gliomas, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Glioma, Glioblastoma Multiforme, Malignant Meningioma

In brief

The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.

Key facts

Study ID

NCT01144247

Run by

Jonsson Comprehensive Cancer Center

People needed

10

Starts

2010-07-01

Expected to finish

2015-07-01

Last updated by the study team

2016-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To participate in this clinical trial, patients must meet the following eligibility criteria:
• Subjects must have a histologically proven diagnosis of malignant glioma or meningioma and been treated with prior standard radiation and chemotherapy. There must be evidence of unequivocal progression by MRI.
• Tumor must be amenable to resection, and surgical resection must be clinically indicated.
• Age at least 18 years.
• Karnofsky performance scale score >60.
• Adequate hematologic function: a) systemic white blood cell count greater than 2 x 103/mm3, b) platelet count greater than 100,000/mm3, c) hematocrit greater than 25%.
• Adequate renal function, with creatinine less than two times the upper limit.
• Adequate hepatic function, with SGOT, alkaline phosphatase, and total bilirubin < 2x upper limit of normal.
• Patients must have an expected survival of at least three months.
• Patients must not have a history of HTLV, HIV, syphilis by RPR, hepatitis B and C.
• Patients must sign an informed consent.

You may not qualify if…

• Patients will be excluded from the trial if the patients:
• have multifocal tumors, bihemispheric tumors, infratentorial tumors, or non-surgically accessible tumors.
• have prior tumor resections where the ventricles were extensively breached.
• are pregnant or breast-feeding women.
• are females of child-bearing potential unable or unwilling to practice adequate birth control methods.
• have contraindications for brain MRI scanning (e.g., intra-ocular metal fragments, cerebral aneurysm clips, pacemaker).
• have concurrent malignancy, excluding curatively treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
• have concurrent systemic infection.
• have any clinically significant, uncontrolled medical illness, as determined by the investigators.
• are unwilling or unable to comply with procedures required in this protocol.

Where it is running

• University of California, Los Angeles — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.